Author

E. Josselin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1

Frequent Co-Authors

R. Castellano· 2 shared A. Goubard· 1 shared A. Krug· 1 shared A. Mueller· 1 shared A.-L. Bailly· 1 shared C. Cayrou· 1 shared C. Costa Da Silva· 1 shared D. Olive· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

R. Castellano

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

P.-L. Bernard, R. Delconte, S. Pastor, V. Laletin, C. Costa Da Silva, A. Goubard, E. Josselin, R. Castellano, A. Krug, J. Vernerey, R. Devillier, D. Olive, E. Verhoeyen, E. Vivier, N. Huntington, , G. Guittard

This study shows that deleting CISH enhances NK cell activation and anti-tumor responses in both mice and human cells, suggesting CISH as a therapeutic target for improving NK cell immunotherapy.

bioRxiv · Mar 16, 2021Immunology

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance

F. Lamballe, F. Ahmad, Y. Vinik, O. Castellanet, F. Daian, A. Mueller, U. Koehler, A.-L. Bailly, E. Josselin, R. Castellano, C. Cayrou, E. Charafe-Jauffret, G. B. Mills, V. Geli, J.-P. Borg, , F. Maina

This study develops a mouse model of TNBC that recapitulates human tumor heterogeneity and identifies a synergistic combination of WEE1 and BCL-XL inhibition as a potential treatment.

bioRxiv · Jun 22, 2020Cancer Biology